Hikma and Civica Rx have struck a five-year supply deal that will see the UK-based firm manufacture and supply the US outfit with 14 essential sterile injectables, as part of Civica’s mission to supply drugs that are often in short supply in US hospitals.
Hikma Strikes Deal To Supply 14 To Civica Rx
Hikma has struck a five-year deal with US firm Civica Rx through which it will supply 14 essential medicines to the operation aimed at tackling shortages in the US.
More from Deals
More from Business
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.